- Previous Close
19.68 - Open
19.38 - Bid 18.73 x 100
- Ask 19.00 x 100
- Day's Range
18.35 - 19.62 - 52 Week Range
15.96 - 30.03 - Volume
246,012 - Avg. Volume
236,981 - Market Cap (intraday)
925.203M - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
-- - EPS (TTM)
-1.89 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
38.14
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
www.enliventherapeutics.comRecent News: ELVN
View MorePerformance Overview: ELVN
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELVN
View MoreValuation Measures
Market Cap
964.41M
Enterprise Value
672.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.11
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.87%
Return on Equity (ttm)
-32.04%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-89.02M
Diluted EPS (ttm)
-1.89
Balance Sheet and Cash Flow
Total Cash (mrq)
313.44M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-46.23M